Tertiary structures of HIV-1 protease and chemical formulas of HIV protease inhibitors. Tertiary structures of HIV-1 protease and chemical formulas of.

Slides:

Advertisements

Similar presentations

Solange Arazi Caillaud. MD Emiliano Bissio. MD María Ester Lázaro. MD.

Advertisements

ARV failure and resistance for the paediatrician

Métodos genotípicos de resistencia a antivirales JOSÉ C. PALOMARES Catedrático Microbiología Jefe de Sección Microbiología Diagnóstica Molecular. H. U.

The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool

HIV Care 2010: The 3 rd Revolution in HIV treatment Chris Farnitano, MD Noon Conference February 11, 2010.

Track B Workshop Controversies in the Management of HIV-positive Adults: A Case-Based Approach Sasisopin Kiertiburanakul, MD, MHS Associate Professor Department.

S.Collins: HIV i-Base TAC training - March 2006 Medical timeline Observation or research ideaY0 Pilot study -design, ethics approval, screen enroll1-2.

Dr Emmanuel Nsutebu Consultant Infectious Diseases Physician Tropical and Infectious Diseases Unit Royal Liverpool Hospital HIV “Myths, controversies and.

HIV-1 Protease HIV-1 Protease is one of the targets in the therapeutic treatment of AIDS. It cleaves the nascent polyproteins of HIV-1 and plays an essential.

Hormonal Contraceptives – Considerations for Women with HIV and AIDS.

The Unique Resistance Profile of Tipranavir Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.

ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.

Introduction to new drugs: I-Base training London - May 2007 Introduction to new drugs African Treatment Advocacy Training 31 May 2007 Simon Collins

HIV:HCV Co-infection Landscape 21 of October, 09 Madrid,Spain GESIDA, Madrid.

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 93 Antiviral Agents II: Drugs for HIV Infection and Related.

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Natural polymorphisms in the protease of HIV-1 isolates explain hypersusceptibility to protease inhibitors A.F. Santos, D.M. Tebit, M.S. Lalonde, A. Ratcliff,

© IAS–USA Johnson VA et al. Top Antivir Med. 2011;19(4): Updates, user notes, and references available at Mutations in the.

Medicines Patent Pool and Seychelles A primer For more information visit:

Measuring Adherence to Chronic Disease Treatment Using Dispensing Data: An Example from Thailand Sauwakon Ratanawijitrasin, PhD Sanita Hirunrassamee, PhD.

Formula? Unit?.  Formula ?  Unit?  Formula?  Unit?

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Why African Americans Must Understand and Participate in Clinical Trials and Vaccines Virginia A. Caine, M.D. Associate Professor of Medicine Division.

Antiretroviral targets in the viral life cycle Viral Replication and Drug targets.

ANTIVIRAL THERAPY DR FATAI OLUYADI USMLEINCLINED.COM 1.

General, Organic, and Biological Chemistry Copyright © 2010 Pearson Education, Inc Viruses Chapter 21 Nucleic Acids and Protein Synthesis.

Retrovirus HIV (humans) Animal viruses resulting in cancer / AIDS 15-39%

© IAS–USA Johnson VA et al. Top Antivir Med. 2013;21(1):4-12. Updates, user notes, and references available at Mutations in the Reverse.

Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 94 Antiviral Agents II: Drugs for HIV Infection and.

Antiretroviral Therapy (ART)

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:

Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses

Giới thiệu về điều trị ARV

Identification of Structural Mechanisms of HIV-1 Protease Specificity Using Computational Peptide Docking: Implications for Drug Resistance Sidhartha.

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

Combating Susceptibility to Drug Resistance

Forecasting for ARVs medicines

Itraconazole tissue and fluid concentrations in humans as multiples of the maximal or simultaneously measured concentration in plasma (μg/ml) after systemic.

Diagram of AmpC from E. coli complexed with acylated ceftazidime (PDB accession number 1IEL) (265) created with Cn3CD, version 4.1 (available at

Supplemental Figure 2 RPMI8226 cells were incubated with increasing concentrations of the respective HIV PI (0-160 mM; Am: amprenavir; At: atazanavir;

History of antiviral drugs approved between January 1959 and April History of antiviral drugs approved between January 1959 and April (A) Approved.

Approximate numbers of cases per 100,000 individuals caused by penicillin resistance for each year (left). Approximate numbers of cases per 100,000 individuals.

Antiviral drug groups for the treatment of 9 infectious diseases.

Mechanisms of drug actions during the viral life cycle.

Virus family, morphology, and transmission of HIV, HBV, HCV, HSV, HCMV, HPV, RSV, VZV, and influenza virus. Virus family, morphology, and transmission.

Glucose concentration-dependent increase of melanin synthesis.

Diagram of the group A streptococcal cell covered with an outer hyaluronic acid capsule and the group A carbohydrate, consisting of a polymer of rhamnose.

Illumina BeadArray. Illumina BeadArray. The SAM contains mm fiber-optic bundles (bottom left). Each bundle is an individual array consisting of.

Fluconazole tissue and fluid concentrations in humans as multiples of the maximal or simultaneously measured concentration in plasma (μg/ml) after systemic.

Number of outbreaks associated with drinking water by water system type and year (n = 780), 1971 to “Other” includes outbreaks associated with bottled.

Percentages of outbreak deficiencies (n = 671) in public water systems (n = 656) by time period, 1971 to 2006, excluding outbreaks associated with Legionella.

Selected host cell processes targeted by Dot/Icm effectors demonstrating the complexity of LCV biogenesis and maintenance as well as the broad range of.

Drug transport mechanism of AcrB.

(Top) Graph illustrating citations in books for Plasmodium falciparum and Plasmodium vivax from 1900 to 2008, generated by use of the tool at

Number of outbreaks associated with drinking water by system type and month (n = 762), 1971 to 2006, excluding outbreaks associated with commercially bottled.

Percentages of 256 clinical isolates obtained from immunocompetent and immunocompromised patients (HIV positive) and from patients with other risk factors.

Fabrizio Dutly, and Martin Altwegg Clin. Microbiol. Rev. 2001; doi:10

Hector H. García et al. Clin. Microbiol. Rev. 2002; doi: /CMR

Three tick vectors of spotted fever group rickettsioses.

Membrane-associated proteins expressed by human epithelial cells that function as receptors for Afa/Dr adhesins. Membrane-associated proteins expressed.

Roberta B. Carey et al. Clin. Microbiol. Rev. 2018; doi: /CMR

Tertiary structures of influenza virus proteins (matrix 2, neuraminidase, and RNA polymerase) and chemical formulas of influenza virus inhibitors. Tertiary.

Tertiary structures of viral integrase and chemical formulas of HIV integrase inhibitors. Tertiary structures of viral integrase and chemical formulas.

The Scorpions primer is an extension of molecular beacons.

Phylogenetic trees for fusion (F) and attachment (G) genes of selected HMPV isolates. Phylogenetic trees for fusion (F) and attachment (G) genes of selected.

HCMV and HSV-1 DNA polymerase structures and chemical formulas of pyrophosphate analogues, 5-substituted 2′-deoxyuridine analogues, and nucleoside analogues.

Tertiary structures of HIV-1 reverse transcriptase and chemical formulas of NRTIs and NNRTIs. (A) HIV-1 RT complexed with dsDNA and zidovudine triphosphate.

Combating Susceptibility to Drug Resistance

Distribution of the four major molecular types of C

Presentation transcript:

Tertiary structures of HIV-1 protease and chemical formulas of HIV protease inhibitors. Tertiary structures of HIV-1 protease and chemical formulas of HIV protease inhibitors. (A) HIV-1 protease dimer complexed with lopinavir (PDB accession number 2Q5K). The side view (left) and top view (right) of structures are presented. (B to K) Chemical formulas of nelfinavir, saquinavir, indinavir, atazanavir, lopinavir, ritonavir, fosamprenavir, amprenavir, darunavir, and tipranavir in the group of protease inhibitors. (L) Chemical formula of cobicistat. Cobicistat is a pharmacoenhancer used with HIV protease inhibitors, but cobicistat alone shows no antiviral activity. Erik De Clercq, and Guangdi Li Clin. Microbiol. Rev. 2016; doi:10.1128/CMR.00102-15